Mesa Laboratories Financials
Mesa Laboratories (MLAB) reported $249.1M in revenue for fiscal year 2026, up 3.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Profit recovery is being driven more by cash-stable, high-gross-margin operations and deleveraging than by rapid top-line growth
FY2024’s earnings collapse did not break the cash engine: free cash flow stayed at$41.6M even as net income fell to-$254.2M , and the simultaneous drop in goodwill from$286.4M to$180.1M points to a mostly non-cash balance-sheet reset rather than a comparable deterioration in collections or core cash generation.
By FY2026, gross margin reached
The balance-sheet posture is materially lighter than in FY2024, with debt-to-equity falling from 2.1x to 0.4x by FY2026, which reduces how much the business depends on borrowed capital to support the same asset base. With cash at
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Mesa Laboratories's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Mesa Laboratories has an operating margin of 7.4%, meaning the company retains $7 of operating profit per $100 of revenue. This below-average margin results in a low score of 16/100, suggesting thin profitability after operating expenses. This is up from 6.8% the prior year.
Mesa Laboratories's revenue grew a modest 3.4% year-over-year to $249.1M. This slow but positive growth earns a score of 58/100.
Mesa Laboratories has a moderate D/E ratio of 0.36. This balance of debt and equity financing earns a leverage score of 47/100.
Mesa Laboratories's current ratio of 1.72 indicates adequate short-term liquidity, earning a score of 49/100. The company can meet its near-term obligations, though with limited headroom.
Mesa Laboratories converts 15.9% of revenue into free cash flow ($39.6M). This strong cash generation earns a score of 83/100.
Mesa Laboratories generates a 3.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 19/100. This is up from -1.2% the prior year.
Mesa Laboratories scores 1.98, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($698.1M) relative to total liabilities ($241.5M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Mesa Laboratories passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Mesa Laboratories generates $6.38 in operating cash flow ($42.8M OCF vs $6.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Mesa Laboratories earns $1.73 in operating income for every $1 of interest expense ($18.5M vs $10.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Mesa Laboratories generated $249.1M in revenue in fiscal year 2026. This represents an increase of 3.4% from the prior year.
Mesa Laboratories's EBITDA was $41.8M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 2.2% from the prior year.
Mesa Laboratories reported $6.7M in net income in fiscal year 2026. This represents an increase of 440.0% from the prior year.
Mesa Laboratories earned $1.21 per diluted share (EPS) in fiscal year 2026. This represents an increase of 436.1% from the prior year.
Cash & Balance Sheet
Mesa Laboratories generated $39.6M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 7.0% from the prior year.
Mesa Laboratories held $26.9M in cash against $67.5M in long-term debt as of fiscal year 2026.
Mesa Laboratories paid $0.64 per share in dividends in fiscal year 2026. That is unchanged from the prior year.
Margins & Returns
Mesa Laboratories's gross margin was 63.5% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 0.9 percentage points from the prior year.
Mesa Laboratories's operating margin was 7.4% in fiscal year 2026, reflecting core business profitability. This is up 0.7 percentage points from the prior year.
Mesa Laboratories's net profit margin was 2.7% in fiscal year 2026, showing the share of revenue converted to profit. This is up 3.5 percentage points from the prior year.
Mesa Laboratories's ROE was 3.6% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 4.8 percentage points from the prior year.
Capital Allocation
Mesa Laboratories invested $20.3M in research and development in fiscal year 2026. This represents an increase of 4.0% from the prior year.
Mesa Laboratories invested $3.3M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 23.5% from the prior year.
Not reported for fiscal year 2026.
MLAB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $249.7M | $249.1M+3.4% | $241.0M+11.5% | $216.2M-1.3% | $219.1M+18.8% | $184.3M+37.6% | $133.9M+13.8% | $117.7M+14.1% | $103.1M+7.2% | $96.2M+2.7% | $93.7M+10.6% | $84.7M+18.7% | $71.3M+35.3% | $52.7M+13.5% | $46.4M+17.2% | $39.6M |
| Cost of Revenue | $89.4M | $90.9M+0.8% | $90.1M+8.6% | $82.9M-2.9% | $85.4M+13.5% | $75.2M+60.4% | $46.9M-10.3% | $52.3M+23.9% | $42.2M+1.6% | $41.6M+2.8% | $40.4M+21.6% | $33.2M+19.0% | $27.9M+32.8% | $21.0M+19.7% | $17.6M+9.1% | $16.1M |
| Gross Profit | $160.3M | $158.3M+4.9% | $150.9M+13.2% | $133.3M-0.3% | $133.7M+22.6% | $109.1M+25.4% | $87.0M+33.1% | $65.4M+7.3% | $60.9M+11.5% | $54.6M+2.6% | $53.2M+3.6% | $51.4M+18.5% | $43.4M+36.9% | $31.7M+9.8% | $28.9M+22.8% | $23.5M |
| R&D Expenses | $20.0M | $20.3M+4.0% | $19.5M+1.1% | $19.3M-5.8% | $20.5M+30.0% | $15.8M+51.8% | $10.4M+63.5% | $6.4M+81.3% | $3.5M-0.9% | $3.5M-14.9% | $4.2M+4.7% | $4.0M+20.6% | $3.3M+42.0% | $2.3M+15.4% | $2.0M+48.0% | $1.4M |
| SG&A Expenses | $78.1M | $78.7M+7.3% | $73.3M+0.6% | $72.9M+0.6% | $72.4M+20.1% | $60.3M+31.7% | $45.8M+19.9% | $38.2M+22.0% | $31.3M+19.2% | $26.3M+15.1% | $22.8M-3.4% | $23.6M+38.5% | $17.1M+48.8% | $11.5M+25.7% | $9.1M+68.3% | $5.4M |
| Operating Income | $22.5M | $18.5M+13.3% | $16.3M+106.0% | -$272.1M-8295.0% | $3.3M-29.4% | $4.7M-62.0% | $12.4M+56.0% | $7.9M-19.0% | $9.8M+348.1% | $2.2M-86.6% | $16.3M-0.1% | $16.3M+2.9% | $15.9M+34.6% | $11.8M-10.1% | $13.1M+5.0% | $12.5M |
| Interest Expense | $10.9M | $10.7M-9.8% | $11.9M+108.2% | $5.7M+19.4% | $4.8M+22.8% | $3.9M-51.6% | $8.0M+45.8% | $5.5M+214.7% | $1.7M-5.6% | $1.9M | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $4.6M | $5.3M-33.2% | $7.9M+137.1% | -$21.4M-1522.6% | -$1.3M-177.5% | $1.7M+275.4% | -$971K-146.6% | $2.1M+83.0% | $1.1M-65.1% | $3.3M+4.8% | $3.1M-29.0% | $4.4M-23.9% | $5.8M+40.5% | $4.1M-9.4% | $4.5M+2.6% | $4.4M |
| Net Income | $4.8M | $6.7M+440.0% | -$2.0M+99.2% | -$254.2M-27438.3% | $930K-50.3% | $1.9M-42.9% | $3.3M+84.1% | $1.8M-76.2% | $7.5M+352.7% | -$3.0M-126.5% | $11.2M+0.1% | $11.2M+16.6% | $9.6M+6.5% | $9.0M+6.5% | $8.4M+6.7% | $7.9M |
| EPS (Diluted) | — | $1.21+436.1% | -$0.36+99.2% | -$47.20-27864.7% | $0.17-51.4% | $0.35-45.3% | $0.64+56.1% | $0.41-78.0% | $1.86+335.4% | -$0.79-127.1% | $2.91-2.0% | $2.97+12.9% | $2.63+5.6% | $2.49+6.0% | $2.35+2.6% | $2.29 |
TTM is the trailing twelve months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MLAB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $427.7M-1.3% | $433.3M-3.0% | $446.8M-32.5% | $661.8M-6.4% | $707.4M+17.6% | $601.5M+47.0% | $409.1M+161.0% | $156.8M-4.5% | $164.1M-4.4% | $171.7M+6.8% | $160.7M+37.0% | $117.3M+20.3% | $97.5M0.0% | $97.5M+92.4% | $50.7M |
| Current Assets | $106.3M+3.5% | $102.7M-6.1% | $109.4M-8.1% | $119.0M-4.3% | $124.3M-59.1% | $303.7M+147.4% | $122.8M+265.2% | $33.6M+5.1% | $32.0M-10.6% | $35.8M-3.8% | $37.2M+25.5% | $29.6M+11.5% | $26.6M+36.6% | $19.5M+1.5% | $19.2M |
| Cash & Equivalents | $26.9M-1.4% | $27.3M-3.2% | $28.2M-14.3% | $32.9M-33.3% | $49.3M-81.3% | $263.9M+224.2% | $81.4M+699.0% | $10.2M+86.2% | $5.5M-6.0% | $5.8M+2.2% | $5.7M+180.0% | $2.0M-63.5% | $5.6M+39.2% | $4.0M-44.3% | $7.2M |
| Inventory | $26.4M+4.0% | $25.4M-22.4% | $32.7M-5.7% | $34.6M+40.8% | $24.6M+120.1% | $11.2M0.0% | $11.2M+65.1% | $6.8M-26.6% | $9.2M-33.5% | $13.9M-1.0% | $14.0M+12.9% | $12.4M+59.8% | $7.8M+39.4% | $5.6M+25.6% | $4.4M |
| Accounts Receivable | $44.1M+5.1% | $42.0M+7.5% | $39.1M-8.2% | $42.6M+3.2% | $41.2M+73.3% | $23.8M+12.6% | $21.1M+68.8% | $12.5M-12.5% | $14.3M-0.1% | $14.3M-6.5% | $15.3M+26.1% | $12.1M+30.9% | $9.3M+9.5% | $8.5M+30.7% | $6.5M |
| Goodwill | $186.9M+2.8% | $181.8M+0.9% | $180.1M-37.1% | $286.4M-1.6% | $291.2M+81.0% | $160.8M+13.6% | $141.5M+113.2% | $66.4M+1.3% | $65.5M-9.2% | $72.2M+9.1% | $66.1M+47.4% | $44.9M+18.5% | $37.9M+60.2% | $23.6M+63.6% | $14.4M |
| Total Liabilities | $241.5M-11.7% | $273.5M-9.3% | $301.4M+12.3% | $268.4M-14.4% | $313.6M+60.6% | $195.2M+3.3% | $189.1M+316.0% | $45.5M-29.8% | $64.7M-12.4% | $73.9M-2.8% | $76.1M+73.5% | $43.8M+32.1% | $33.2M-25.9% | $44.8M+560.3% | $6.8M |
| Current Liabilities | $61.9M-62.2% | $164.0M+270.0% | $44.3M+2.2% | $43.4M-9.8% | $48.1M+47.5% | $32.6M+25.3% | $26.0M+9.9% | $23.7M+36.8% | $17.3M+4.4% | $16.6M-30.9% | $24.0M+63.5% | $14.7M+43.5% | $10.2M+119.1% | $4.7M+9.4% | $4.3M |
| Long-Term Debt | $67.5M-5.3% | $71.3M | N/A | N/A | N/A | N/A | N/A | $20.6M-53.8% | $44.6M-16.8% | $53.7M+27.0% | $42.3M+81.7% | $23.3M+40.9% | $16.5M+312.5% | $4.0M | N/A |
| Total Equity | $186.2M+16.5% | $159.8M+9.9% | $145.4M-63.0% | $393.5M-0.1% | $393.8M-3.1% | $406.2M+84.6% | $220.0M+97.7% | $111.3M+12.0% | $99.4M+1.6% | $97.8M+15.5% | $84.7M+15.2% | $73.5M+14.2% | $64.3M+22.0% | $52.8M+20.1% | $43.9M |
| Retained Earnings | -$185.7M+1.7% | -$188.9M-3.0% | -$183.5M-347.3% | $74.2M-3.2% | $76.7M+5.8% | $72.5M+0.1% | $72.4M-1.3% | $73.3M+7.4% | $68.3M-7.3% | $73.7M+13.6% | $64.8M+15.8% | $56.0M+15.2% | $48.6M+16.9% | $41.5M+16.2% | $35.7M |
MLAB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $55.7M | $42.8M-8.5% | $46.8M+6.1% | $44.1M+57.7% | $28.0M-28.7% | $39.2M+5.8% | $37.1M+37.4% | $27.0M-11.7% | $30.6M+18.8% | $25.7M+48.6% | $17.3M+2.4% | $16.9M+56.3% | $10.8M-12.6% | $12.4M+8.5% | $11.4M-8.7% | $12.5M |
| Capital Expenditures | $2.8M | $3.3M-23.5% | $4.2M+65.5% | $2.6M-43.5% | $4.5M+2.5% | $4.4M+122.5% | $2.0M+33.0% | $1.5M+18.7% | $1.3M-54.9% | $2.8M | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $52.9M | $39.6M-7.0% | $42.6M+2.4% | $41.6M+77.3% | $23.4M-32.6% | $34.8M-0.8% | $35.1M+37.6% | $25.5M-13.0% | $29.3M+27.8% | $22.9M | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$2.8M | -$3.3M+27.8% | -$4.5M+94.5% | -$81.3M-756.4% | -$9.5M+96.9% | -$305.2M-15222.5% | -$2.0M+98.9% | -$185.6M-4683.1% | -$3.9M+77.4% | -$17.2M+6.6% | -$18.4M+42.2% | -$31.8M | N/A | N/A | N/A | N/A |
| Financing Cash Flow | -$43.9M | -$41.9M+6.0% | -$44.5M-235.5% | $32.8M+198.5% | -$33.3M-163.4% | $52.6M-64.0% | $146.2M-36.8% | $231.3M+1167.2% | -$21.7M-140.2% | -$9.0M-882.0% | $1.2M-93.8% | $18.6M | N/A | N/A | N/A | N/A |
| Dividends Paid | $3.5M | $3.5M+1.6% | $3.5M+0.6% | $3.4M+1.2% | $3.4M+2.0% | $3.3M+5.5% | $3.2M+16.3% | $2.7M+10.6% | $2.5M+2.0% | $2.4M+2.5% | $2.4M+2.3% | $2.3M+5.5% | $2.2M+9.7% | $2.0M+9.6% | $1.8M+10.3% | $1.6M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $22K-78.4% | $102K-82.9% | $597K |
TTM is the trailing twelve months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MLAB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.5%+0.9pp | 62.6%+1.0pp | 61.6%+0.6pp | 61.0%+1.8pp | 59.2%-5.8pp | 65.0%+9.4pp | 55.5%-3.5pp | 59.1%+2.3pp | 56.8%-0.1pp | 56.8%-3.9pp | 60.7%-0.1pp | 60.8%+0.7pp | 60.1%-2.1pp | 62.2%+2.8pp | 59.4% |
| Operating Margin | 7.4%+0.7pp | 6.8% | -125.8% | 1.5%-1.0pp | 2.5%-6.7pp | 9.2%+2.5pp | 6.7%-2.7pp | 9.5%+7.2pp | 2.3%-15.2pp | 17.4%-1.9pp | 19.3%-3.0pp | 22.2%-0.1pp | 22.4%-5.9pp | 28.2%-3.3pp | 31.5% |
| Net Margin | 2.7%+3.5pp | -0.8% | -117.6% | 0.4%-0.6pp | 1.0%-1.4pp | 2.4%+0.9pp | 1.5%-5.8pp | 7.3%+10.3pp | -3.1%-15.0pp | 11.9%-1.2pp | 13.2%-0.2pp | 13.4%-3.6pp | 17.1%-1.1pp | 18.2%-1.8pp | 20.0% |
| Return on Equity | 3.6%+4.8pp | -1.2%+173.6pp | -174.9%-175.1pp | 0.2%-0.2pp | 0.5%-0.3pp | 0.8%0.0pp | 0.8%-5.9pp | 6.7%+9.7pp | -3.0%-14.4pp | 11.4%-1.8pp | 13.2%+0.2pp | 13.0%-1.0pp | 14.0%-2.0pp | 16.0%-2.0pp | 18.0% |
| Return on Assets | 1.6%+2.0pp | -0.5%+56.4pp | -56.9%-57.0pp | 0.1%-0.1pp | 0.3%-0.3pp | 0.5%+0.1pp | 0.4%-4.3pp | 4.8%+6.6pp | -1.8%-8.3pp | 6.5%-0.4pp | 7.0%-1.2pp | 8.2%-1.1pp | 9.2%+0.6pp | 8.7%-7.0pp | 15.6% |
| Current Ratio | 1.72+1.1x | 0.63-1.8x | 2.47-0.3x | 2.74+0.2x | 2.59-6.7x | 9.32+4.6x | 4.72+3.3x | 1.42-0.4x | 1.85-0.3x | 2.16+0.6x | 1.55-0.5x | 2.02-0.6x | 2.60-1.6x | 4.17-0.3x | 4.50 |
| Debt-to-Equity | 0.36-0.1x | 0.45-1.6x | 2.07+1.4x | 0.68-0.1x | 0.80+0.3x | 0.48-0.4x | 0.86+0.7x | 0.19-0.3x | 0.45-0.1x | 0.550.0x | 0.50+0.2x | 0.32+0.1x | 0.26+0.2x | 0.08-0.1x | 0.15 |
| FCF Margin | 15.9%-1.8pp | 17.7%-1.6pp | 19.2%+8.5pp | 10.7%-8.2pp | 18.9%-7.3pp | 26.2%+4.5pp | 21.7%-6.7pp | 28.4%+4.6pp | 23.8% | N/A | N/A | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Mesa Laboratories Ranks
Frequently Asked Questions
What is Mesa Laboratories's annual revenue?
Mesa Laboratories (MLAB) reported $249.1M in total revenue for fiscal year 2026. This represents a 3.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Mesa Laboratories's revenue growing?
Mesa Laboratories (MLAB) revenue grew by 3.4% year-over-year, from $241.0M to $249.1M in fiscal year 2026.
Is Mesa Laboratories profitable?
Yes, Mesa Laboratories (MLAB) reported a net income of $6.7M in fiscal year 2026, with a net profit margin of 2.7%.
What is Mesa Laboratories's EBITDA?
Mesa Laboratories (MLAB) had EBITDA of $41.8M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Mesa Laboratories have?
As of fiscal year 2026, Mesa Laboratories (MLAB) had $26.9M in cash and equivalents against $67.5M in long-term debt.
What is Mesa Laboratories's gross margin?
Mesa Laboratories (MLAB) had a gross margin of 63.5% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Mesa Laboratories's operating margin?
Mesa Laboratories (MLAB) had an operating margin of 7.4% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Mesa Laboratories's net profit margin?
Mesa Laboratories (MLAB) had a net profit margin of 2.7% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
Does Mesa Laboratories pay dividends?
Yes, Mesa Laboratories (MLAB) paid $0.64 per share in dividends during fiscal year 2026.
What is Mesa Laboratories's return on equity (ROE)?
Mesa Laboratories (MLAB) has a return on equity of 3.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Mesa Laboratories's free cash flow?
Mesa Laboratories (MLAB) generated $39.6M in free cash flow during fiscal year 2026. This represents a -7.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Mesa Laboratories's operating cash flow?
Mesa Laboratories (MLAB) generated $42.8M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Mesa Laboratories's total assets?
Mesa Laboratories (MLAB) had $427.7M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Mesa Laboratories's capital expenditures?
Mesa Laboratories (MLAB) invested $3.3M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Mesa Laboratories spend on research and development?
Mesa Laboratories (MLAB) invested $20.3M in research and development during fiscal year 2026.
What is Mesa Laboratories's current ratio?
Mesa Laboratories (MLAB) had a current ratio of 1.72 as of fiscal year 2026, which is generally considered healthy.
What is Mesa Laboratories's debt-to-equity ratio?
Mesa Laboratories (MLAB) had a debt-to-equity ratio of 0.36 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mesa Laboratories's return on assets (ROA)?
Mesa Laboratories (MLAB) had a return on assets of 1.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Mesa Laboratories's Altman Z-Score?
Mesa Laboratories (MLAB) has an Altman Z-Score of 1.98, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Mesa Laboratories's Piotroski F-Score?
Mesa Laboratories (MLAB) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mesa Laboratories's earnings high quality?
Mesa Laboratories (MLAB) has an earnings quality ratio of 6.38x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Mesa Laboratories cover its interest payments?
Mesa Laboratories (MLAB) has an interest coverage ratio of 1.73x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Mesa Laboratories?
Mesa Laboratories (MLAB) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.